Breast Biopsy Devices Market - Global Forecast To 2030
商品番号 : SMB-42141
| 出版社 | MarketsandMarkets |
| 出版年月 | 2025年5月 |
| ページ数 | 290 |
| 図表数 | 324 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
| 種別 | 英文調査報告書 |
- 本レポートは、乳房生検用デバイス市場を製品、手順、用途、エンドユーザー、地域別に調査しています。
- 本レポートでは、市場の成長に影響を与える要因（推進要因、抑制要因、機会、課題）を分析しています。
- 本レポートでは、利害関係者にとっての市場機会と課題を評価し、市場リーダーの競争環境を詳細に説明しています。
- 本レポートでは、マイクロマーケットの成長傾向、見通し、そして世界の乳房生検用デバイス市場への貢献について調査しています。
- 本レポートでは、5つの主要地域における市場セグメントの収益予測を行っています。
The global market for breast biopsy devices is expected to reach USD 3,261.7 million by 2030 from USD 2,384.1 million in 2025, representing a CAGR of 6.5% during the forecast period. The market is benefiting from a combination of factors, including rising breast cancer rates, increased awareness of the importance of early detection, and the growing preference for minimally invasive diagnostic procedures. Additionally, state and provincial screening programs are significantly improving the rate of screenings among women for potential breast cancer.
世界の乳房生検用デバイス市場は、2025年の23億8,410万米ドルから2030年には32億6,170万米ドルに達し、予測期間中に年平均成長率（CAGR）6.5%で成長すると予測されています。市場は、乳がん罹患率の上昇、早期発見の重要性に対する意識の高まり、低侵襲診断法への関心の高まりなど、複数の要因の恩恵を受けています。さらに、州および地方自治体による乳がんスクリーニングプログラムにより、女性の乳がんスクリーニング受診率が大幅に向上しています。
The biopsy needles segment held the largest share of the market in 2024.
Based on type, the breast biopsy devices market is divided into several segments: biopsy needles, guidance systems, biopsy tables, localization wires, assay kits, liquid biopsy instruments, and other devices. Among these, the biopsy needles segment holds a significant share of the market. Biopsy needles are essential tools for diagnosing breast cancer, as they collect tissue samples for histopathological analysis with high accuracy and minimal invasiveness. They can be utilized in core-needle biopsy (CNB), fine-needle aspiration biopsy (FNAB), and vacuum-assisted biopsy (VAB), each designed for specific clinical scenarios and the varying characteristics of the lesions. Biopsy needles are preferred because they provide diagnostic results with less discomfort for the patient and require less time for both the procedure and recovery compared to surgical biopsies.
The needle breast biopsy procedure segment accounted for the largest market share in 2024.
Based on procedures, the breast biopsy devices market can be broadly categorized into three types: needle breast biopsy, open surgical breast biopsy, and liquid breast biopsy. The growth of the needle breast biopsy segment is driven by several key factors. These include rising breast cancer rates, a greater emphasis on early and accurate diagnosis, and an increasing preference among patients for minimally invasive procedures. Advancements in technology, particularly in image guidance and needle design, have enhanced the accuracy of needle breast biopsies while minimizing discomfort and inconvenience. This has made the procedure more acceptable and feasible for patients. Furthermore, the establishment of breast cancer screening programs, more favorable reimbursement policies, and heightened awareness of women’s health issues are also contributing to market growth. Additionally, the preference for outpatient care and the growing interest in cost-effective diagnostic options have led to broader acceptance of needle breast biopsies across various healthcare settings.
The liquid biopsy segment is projected to register the highest CAGR during the forecast period.
The breast biopsy devices market is primarily categorized into three main techniques: image-guided biopsy, liquid biopsy, and other methods. The liquid biopsy segment is experiencing growth due to the increasing demand for non-invasive, accurate, and real-time cancer diagnostic solutions. Liquid biopsy processes detect circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in the blood, making them less invasive than traditional tissue biopsies. This allows for earlier diagnoses, better tracking of treatment responses, and effective monitoring for recurrence or progression of the disease. Several factors are driving the growth of the liquid biopsy market, including the rising incidence of breast cancer, the advancement of precision (or personalized) medicine, and improvements in molecular diagnostic technologies, particularly through next-generation sequencing (NGS) and digital PCR. The increasing clinical utility and routine application of liquid biopsies, along with a growing awareness of their benefits and supportive regulatory policies, are further promoting the global adoption of these technologies.
The early cancer screening segment dominated the market in 2024.
The breast biopsy market can be broadly categorized based on its applications into four main areas: early cancer screening, therapy selection, treatment monitoring, and recurrence monitoring. Early cancer screening holds the largest market share as it plays a crucial role in reducing mortality rates and improving treatment outcomes by detecting cancer at the earliest and most treatable stage. The rising incidence of cancer globally, particularly among vulnerable and aging populations, has increased the need for effective illness monitoring. Consequently, advancements in technology will serve as a significant driver for early and proactive health monitoring and diagnosis.
Asia Pacific is expected to register a significant growth rate in the market during the forecast period.
The breast biopsy market is experiencing the highest growth in the Asia Pacific region due to several converging factors. These include an increasing incidence of breast cancer, the development of healthcare infrastructure, and greater awareness of the importance of early cancer detection. Countries such as China, India, and Japan are making significant investments in interventional and diagnostic imaging, which is creating a demand for advanced biopsy technologies. Additionally, government support, improved access to medical care in rural areas, and the expansion of global medical device companies promoting their products in emerging markets are driving this adoption. Furthermore, the region’s large population and rising healthcare spending are key drivers of its double-digit market growth.
A breakdown of the primary participants referred to for this report is provided below:
- By Company Type: Tier 1 (40%), Tier 2 (30%), and Tier 3 (30%)
- By Designation: C-level Executives (27%), Director-level Executives (18%), and Other Designations (55%)
- By Region: North America (50%), Europe (20%), Asia Pacific (15%), Latin America (10%), and the Middle East & Africa (5%)
Prominent players in this market are Hologic Inc. (US), Danaher Corporation (US), Argon Medical Devices (US), Merit Medical Systems (US), Menarini-Silicon Biosystems (Italy), Varian Medical Systems, Inc. (Germany), Planmed Oy (Finland), Sterylab S.R.L (Italy), Biocept, Inc. (US), Bio-Rad Laboratories, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), QIAGEN (Germany), and Exact Sciences Corporation (US).
Research Coverage
- The report studies the breast biopsy devices market by product, procedure, application, end user, and region.
- The report analyzes factors affecting market growth (drivers, restraints, opportunities, and challenges).
- The report evaluates the market opportunities and challenges for stakeholders and details the competitive landscape for market leaders.
- The report studies micromarkets with respect to their growth trends, prospects, and contributions to the global breast biopsy devices market.
- The report forecasts the revenue of market segments with respect to five major regions.
Key Benefits of Buying the Report:
The report is designed to assist both new entrants and established market leaders, as well as smaller companies in the breast biopsy devices sector, in making informed investment decisions. It provides comprehensive data that supports risk evaluation and validated investment strategies. The report features detailed market segmentation based on end users and regional aspects, enabling you to focus on specific segments. Additionally, it offers thorough coverage and analysis of trends, challenges, growth opportunities, and future prospects, ensuring that your decisions are well-informed and considerate of all relevant factors.
The report provides insights into the following pointers:
- Analysis of key drivers (ongoing innovations in biopsy needle designs and liquid biopsy technologies), restraints (high costs associated with advanced biopsy equipment and imaging technologies and stringent regulatory approval procedures), opportunities (technological advancements in imaging technology), and challenges (accuracy and reliability of certain biopsy procedures), influencing the growth of the breast biopsy devices market.
- Product Development/Innovation: Detailed insights into upcoming technologies, R&D activities, and new product & service launches in the breast biopsy devices market.
- Market Diversification: Exhaustive information about untapped geographies, new products, recent developments, and investments in the breast biopsy devices market.
- Market Development: Comprehensive information about lucrative markets—the report analyzes the breast biopsy devices market across varied regions.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players such as Hologic Inc. (US), Danaher Corporation (US), Argon Medical Devices (US), Merit Medical Systems (US), Menarini-Silicon Biosystems (Italy), Varian Medical Systems, Inc. (Germany), Planmed Oy (Finland), Sterylab S.R.L (Italy), QIAGEN (Germany), and Biocept, Inc. (US), among others
Table of Contents
1 INTRODUCTION 26
1.1 STUDY OBJECTIVES 26
1.2 MARKET DEFINITION 26
1.3 STUDY SCOPE 27
1.3.1 MARKETS COVERED & REGIONAL SCOPE 27
1.3.2 INCLUSIONS & EXCLUSIONS 28
1.3.3 YEARS CONSIDERED 28
1.4 CURRENCY CONSIDERED 28
1.5 STUDY LIMITATIONS 29
1.6 STAKEHOLDERS 29
1.7 SUMMARY OF CHANGES 29
2 RESEARCH METHODOLOGY 31
2.1 RESEARCH DATA 31
2.1.1 SECONDARY DATA 32
2.1.1.1 Key sources of secondary data 32
2.1.1.2 Objectives of secondary research 33
2.1.1.3 Key data from secondary sources 34
2.1.2 PRIMARY DATA 35
2.1.2.1 Key primary sources 35
2.1.2.2 Key objectives of primary research 35
2.1.2.3 Key industry insights 36
2.2 MARKET SIZE ESTIMATION 37
2.2.1 BOTTOM-UP APPROACH (REVENUE SHARE ANALYSIS) 39
2.2.1.1 Company revenue estimation approach 39
2.2.1.2 Customer-based market estimation 40
2.2.2 TOP-DOWN APPROACH 40
2.3 DATA TRIANGULATION 43
2.4 MARKET SHARE ASSESSMENT 44
2.5 STUDY ASSUMPTIONS 44
2.5.1 MARKET ASSUMPTIONS 44
2.5.2 GROWTH RATE ASSUMPTIONS 44
2.6 RESEARCH LIMITATIONS 45
2.7 RISK ANALYSIS 45
3 EXECUTIVE SUMMARY 46
4 PREMIUM INSIGHTS 50
4.1 BREAST BIOPSY DEVICES MARKET OVERVIEW 50
4.2 BREAST BIOPSY DEVICES MARKET, BY REGION, 2025 VS. 2030 (USD MILLION) 51
4.3 EUROPE: BREAST BIOPSY DEVICES MARKET, BY REGION AND APPLICATION, 2024 52
4.4 GEOGRAPHIC SNAPSHOT OF BREAST BIOPSY DEVICES MARKET 53
5 MARKET OVERVIEW 54
5.1 INTRODUCTION 54
5.2 MARKET DYNAMICS 54
5.2.1 DRIVERS 55
5.2.1.1 Growing incidence of breast cancer 55
5.2.1.2 Expansion of private diagnostic chains and imaging centers 55
5.2.1.3 Increasing demand for minimally invasive and non-invasive procedures 56
5.2.1.4 Growing awareness regarding early detection of breast cancer 56
5.2.1.5 Improved reimbursement scenario 57
5.2.2 RESTRAINTS 58
5.2.2.1 High cost of liquid biopsy tests 58
5.2.2.2 Stringent regulatory approval procedures 59
5.2.3 OPPORTUNITIES 59
5.2.3.1 Technological advancements 59
5.2.3.2 Growing collaboration and financial support from public and private sectors 60
5.2.4 CHALLENGES 61
5.2.4.1 Shortage of skilled professionals 61
5.3 REGULATORY ANALYSIS 61
5.3.1 REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS 62
5.3.2 REGULATORY LANDSCAPE 63
5.3.2.1 North America 64
5.3.2.1.1 US 64
5.3.2.1.2 Canada 65
5.3.2.2 Europe 65
5.3.2.3 Asia Pacific 66
5.3.2.3.1 Japan 66
5.3.2.3.2 China 67
5.3.2.3.3 India 68
5.4 VALUE CHAIN ANALYSIS 68
5.5 SUPPLY CHAIN ANALYSIS 70
5.5.1 PROMINENT COMPANIES 70
5.5.2 SMALL & MEDIUM-SIZED ENTERPRISES 70
5.5.3 END USERS 70
5.6 ECOSYSTEM ANALYSIS 71
5.7 TECHNOLOGY ANALYSIS 72
5.7.1 KEY TECHNOLOGIES 72
5.7.1.1 Ultrasound 72
5.7.1.2 Mammography-guided stereotactic biopsy 73
5.7.1.3 MRI 73
5.7.1.4 Contrast-enhanced mammography (CEM) guidance 73
5.7.2 COMPLEMENTARY TECHNOLOGIES 73
5.7.2.1 Gamma-guided biopsy systems 73
5.7.2.2 Molecular breast imaging (MBI)-guided biopsy 74
5.7.3 ADJACENT TECHNOLOGIES 74
5.7.3.1 Surgical oncology technologies 74
5.7.3.2 Cryoablation and other minimally invasive ablation technologies 74
5.8 TRADE ANALYSIS 75
5.8.1 IMPORT DATA 75
5.8.2 EXPORT DATA 75
5.9 PATENT ANALYSIS 76
5.10 PORTER’S FIVE FORCES ANALYSIS 77
5.10.1 THREAT OF NEW ENTRANTS 78
5.10.2 THREAT OF SUBSTITUTES 78
5.10.3 BARGAINING POWER OF SUPPLIERS 78
5.10.4 BARGAINING POWER OF BUYERS 78
5.10.5 INTENSITY OF COMPETITIVE RIVALRY 78
5.11 PRICING ANALYSIS 79
5.11.1 AVERAGE SELLING PRICE TREND OF BREAST BIOPSY DEVICES, BY REGION 79
5.11.2 AVERAGE SELLING PRICE OF BREAST BIOPSY DEVICES, BY APPLICATION 81
5.12 CASE STUDY ANALYSIS 82
5.12.1 CASE STUDY 1: PET-GUIDED BREAST BIOPSY 82
5.12.2 CASE STUDY 2: EARLY-STAGE BREAST CANCER AMID COVID PANDEMIC 82
5.12.3 CASE STUDY 3: SAMPLING MULTIPLE SMALL LESIONS IN DENSE BREAST TISSUE 83
5.13 KEY CONFERENCES & EVENTS, 2025–2026 83
5.14 KEY STAKEHOLDERS & BUYING CRITERIA 84
5.14.1 KEY STAKEHOLDERS 84
5.14.2 BUYING CRITERIA 85
5.15 IMPACT OF 2025 US TARIFF ON BREAST BIOPSY DEVICES MARKET 86
5.15.1 INTRODUCTION 86
5.15.2 KEY TARIFF RATES 86
5.15.3 PRICE IMPACT ANALYSIS 87
5.15.4 IMPACT ON COUNTRY/REGION 87
5.15.4.1 US 87
5.15.4.2 Europe 88
5.15.4.3 Asia Pacific 88
5.15.5 IMPACT ON END-USE INDUSTRIES 88
5.16 IMPACT OF GENERATIVE AI/AI ON BREAST BIOPSY DEVICES MARKET 89
5.17 INVESTMENT & FUNDING SCENARIO 90
6 BREAST BIOPSY DEVICES MARKET, BY PROCEDURE 92
6.1 INTRODUCTION 93
6.2 NEEDLE BREAST BIOPSY 93
6.2.1 CORE NEEDLE BIOPSY 94
6.2.1.1 Procedural advantages of guidance system-based biopsy to drive revenue growth 94
6.2.2 VACUUM-ASSISTED BIOPSY (VAB) 95
6.2.2.1 High diagnostic specificity and accuracy of technique to boost demand 95
6.2.3 FINE NEEDLE ASPIRATION BIOPSY (FNAB) 96
6.2.3.1 Drawbacks associated with procedure to limit market growth 96
6.3 OPEN SURGICAL BREAST BIOPSY 97
6.3.1 EXCISIONAL BIOPSY 98
6.3.1.1 Risk of post-operative complications to hinder market growth 98
6.3.2 INCISIONAL BIOPSY 98
6.3.2.1 Longer recovery period associated with incisional biopsy to restrict growth 98
6.4 LIQUID BREAST BIOPSY 99
6.4.1 CIRCULATING TUMOR CELLS 100
6.4.1.1 Ability to provide important information on molecular properties of breast tumors to boost market 100
6.4.2 CIRCULATING TUMOR DNA (CTDNA) 100
6.4.2.1 Low concentrations of ctDNA to make screening for clinically relevant mutations challenging 100
6.4.3 OTHER BIOMARKERS 101
7 BREAST BIOPSY DEVICES MARKET, BY PRODUCT 103
7.1 INTRODUCTION 104
7.2 BIOPSY NEEDLES 105
7.2.1 CORE NEEDLES 106
7.2.1.1 Early detection through core needle biopsy to boost growth 106
7.2.2 FINE ASPIRATION NEEDLES 107
7.2.2.1 Accurate clinical decisions for early cancer diagnosis to drive demand for fine aspiration needles 107
7.2.3 VACUUM-ASSISTED BIOPSY NEEDLES 108
7.2.3.1 Enhanced accuracy with vacuum-assisted tissue sampling to drive adoption 108
7.3 BIOPSY EQUIPMENT 108
7.3.1 CORE BIOPSY EQUIPMENT 110
7.3.1.1 Ability to streamline breast diagnosis with core biopsy technology to boost demand 110
7.3.2 VACUUM-ASSISTED BIOPSY EQUIPMENT 111
7.3.2.1 Advantages of VAB in breast biopsy to drive market growth 111
7.4 GUIDANCE SYSTEMS 111
7.4.1 MAMMOGRAPHY-GUIDED STEREOTACTIC BIOPSY 112
7.4.1.1 Advantages of technique to boost adoption in coming years 112
7.4.2 ULTRASOUND-GUIDED BIOPSY 113
7.4.2.1 Ability to create fine-grained pictures of breasts to drive growth 113
7.4.3 MRI-GUIDED BIOPSY 114
7.4.3.1 High cost and low specificity to affect demand 114
7.5 BIOPSY TABLES 114
7.5.1 GROWING USE OF BIOPSY TABLES TO PERFORM STEREOTACTIC BIOPSY PROCEDURES TO FAVOR MARKET GROWTH 114
7.6 ASSAY KITS 115
7.6.1 PRODUCT APPROVALS AND LAUNCHES TO DRIVE SEGMENTAL GROWTH 115
7.7 LIQUID BIOPSY INSTRUMENTS 116
7.7.1 ONGOING RESEARCH AND CLINICAL TRIALS TO DELIVER NOVEL SOLUTIONS IN MARKET 116
7.8 LOCALIZATION WIRES 117
7.8.1 WIDE USAGE OF LOCALIZATION WIRES TO LOCATE BREAST ABNORMALITIES AND LUMPS TO BOOST MARKET 117
7.9 OTHER PRODUCTS 118
8 BREAST BIOPSY MARKET, BY APPLICATION 119
8.1 INTRODUCTION 120
8.2 EARLY CANCER SCREENING 120
8.2.1 GROWING AWARENESS ABOUT EARLY CANCER DETECTION TO DRIVE SEGMENT GROWTH 120
8.3 THERAPY SELECTION 121
8.3.1 ABILITY OF PERSONALIZED THERAPY SELECTION TO ENHANCE TREATMENT EFFICACY TO DRIVE DEMAND 121
8.4 TREATMENT MONITORING 122
8.4.1 GROWING POPULARITY OF REAL-TIME TREATMENT MONITORING TO BOOST MARKET 122
8.5 RECURRENCE MONITORING 122
8.5.1 UNMET CLINICAL NEEDS TO CREATE OPPORTUNITIES FOR PLAYERS IN MARKET 122
9 BREAST BIOPSY DEVICES MARKET, BY END USER 124
9.1 INTRODUCTION 125
9.2 HOSPITALS & CLINICS 125
9.2.1 RISING DEMAND FOR QUICK AND ACCURATE DIAGNOSIS TO BOOST MARKET 125
9.3 IMAGING CLINICS & DIAGNOSTIC CENTERS 126
9.3.1 RISING NUMBER OF PRIVATE IMAGING CENTERS TO CONTRIBUTE TO MARKET GROWTH 126
9.4 BREAST CARE CENTERS 127
9.4.1 INCREASING POPULARITY OF BREAST CARE CENTERS IN DEVELOPED COUNTRIES TO BOOST MARKET 127
10 BREAST BIOPSY DEVICES MARKET, BY REGION 129
10.1 INTRODUCTION 130
10.2 NORTH AMERICA 132
10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 132
10.2.2 US 137
10.2.2.1 US to dominate North America breast biopsy devices market during forecast period 137
10.2.3 CANADA 140
10.2.3.1 Surge in incidence of breast cancer and favorable government guidelines to support market growth 140
10.3 EUROPE 142
10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 143
10.3.2 GERMANY 147
10.3.2.1 Favorable changes in reimbursement scenario to fuel adoption of technologically advanced products in Germany 147
10.3.3 UK 149
10.3.3.1 Initiatives by public & private organizations to increase awareness about breast cancer to drive growth 149
10.3.4 FRANCE 152
10.3.4.1 Rising geriatric population to support market growth 152
10.3.5 ITALY 154
10.3.5.1 Evolving regulatory scenario for breast biopsy to boost market 154
10.3.6 SPAIN 157
10.3.6.1 Increased funding scenario to propel market growth 157
10.3.7 REST OF EUROPE 159
10.4 ASIA PACIFIC 161
10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 162
10.4.2 CHINA 167
10.4.2.1 Increasing patient pool and government initiatives for healthcare development to fuel market growth 167
10.4.3 JAPAN 170
10.4.3.1 Presence of universal healthcare reimbursement scenario and rising breast cancer cases 170
10.4.4 INDIA 172
10.4.4.1 Government initiatives to improve female health to drive market growth in India 172
10.4.5 AUSTRALIA 175
10.4.5.1 Rising research investments and awareness campaigns to support market growth 175
10.4.6 SOUTH KOREA 177
10.4.6.1 Rising R&D and promising clinical trials in country to positively impact market growth 177
10.4.7 REST OF ASIA PACIFIC 179
10.5 LATIN AMERICA 181
10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 182
10.5.2 BRAZIL 186
10.5.2.1 Key market in Latin America owing to modernization of healthcare facilities 186
10.5.3 MEXICO 188
10.5.3.1 Availability of advanced care and increasing awareness programs to fuel market growth 188
10.5.4 REST OF LATIN AMERICA 190
10.6 MIDDLE EAST & AFRICA 192
10.6.1 IMPROVING HEALTHCARE INFRASTRUCTURE AND INCREASING PUBLIC–PRIVATE INVESTMENTS TO DRIVE MARKET GROWTH IN MEA REGION 192
10.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 193
10.6.3 GCC COUNTRIES 197
10.6.3.1 Growing healthcare infrastructure to fuel market growth 197
10.6.4 REST OF MIDDLE EAST & AFRICA 199
11 COMPETITIVE LANDSCAPE 202
11.1 INTRODUCTION 202
11.2 KEY PLAYER STRATEGY/RIGHT TO WIN 202
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS 203
11.3 REVENUE ANALYSIS, 2020–2024 204
11.4 MARKET SHARE ANALYSIS, 2024 205
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS (2024) 208
11.5.1 STARS 208
11.5.2 EMERGING LEADERS 208
11.5.3 PERVASIVE PLAYERS 208
11.5.4 PARTICIPANTS 208
11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 210
11.5.5.1 Company footprint 210
11.5.5.2 Region footprint 211
11.5.5.3 Product footprint 212
11.5.5.4 Procedure footprint 213
11.5.5.5 Application footprint 214
11.5.5.6 End-user footprint 215
11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES (2024) 216
11.6.1 PROGRESSIVE COMPANIES 216
11.6.2 RESPONSIVE COMPANIES 216
11.6.3 DYNAMIC COMPANIES 216
11.6.4 STARTING BLOCKS 216
11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 218
11.6.5.1 Detailed list of key startups/SMEs 218
11.6.5.2 Competitive benchmarking of startup/SME players, by region 218
11.6.5.3 Competitive benchmarking of startup/SME players, product 219
11.7 COMPANY VALUATION & FINANCIAL METRICS 220
11.7.1 FINANCIAL METRICS 220
11.7.2 COMPANY VALUATION 220
11.8 BRAND/PRODUCT COMPARISON 221
11.9 COMPETITIVE SCENARIO 222
11.9.1 THIS SEGMENT INCLUDES THE GROWTH STRATEGIES ADOPTED BY MAJOR PLAYERS IN THE BREAST BIOPSY DEVICES MARKET BETWEEN JANUARY 2020 AND MAY 2025. 222
11.9.2 PRODUCT LAUNCHES & APPROVALS 222
11.9.3 DEALS 223
12 COMPANY PROFILES 224
12.1 KEY PLAYERS 224
12.1.1 HOLOGIC, INC. 224
12.1.1.1 Business overview 224
12.1.1.2 Products offered 225
12.1.1.2.1 Deals 226
12.1.1.3 MnM view 227
12.1.1.3.1 Key strengths 227
12.1.1.3.2 Strategic choices 227
12.1.1.3.3 Weaknesses & competitive threats 227
12.1.2 DANAHER CORPORATION 228
12.1.2.1 Business overview 228
12.1.2.2 Products offered 229
12.1.2.3 Recent developments 230
12.1.2.3.1 Product launches & approvals 230
12.1.2.3.2 Deals 231
12.1.2.4 MnM view 231
12.1.2.4.1 Key strengths 231
12.1.2.4.2 Strategic choices 232
12.1.2.4.3 Weaknesses & competitive threats 232
12.1.3 BECTON, DICKINSON AND COMPANY 233
12.1.3.1 Business overview 233
12.1.3.2 Products offered 234
12.1.3.3 MnM View 235
12.1.3.3.1 Key strengths 235
12.1.3.3.2 Strategic choices 235
12.1.3.3.3 Weaknesses & competitive threats 235
12.1.4 ARGON MEDICAL 236
12.1.4.1 Business overview 236
12.1.4.2 Products offered 236
12.1.4.3 Recent developments 237
12.1.4.3.1 Product launches & approvals 237
12.1.4.3.2 Deals 237
12.1.4.4 MnM view 238
12.1.4.4.1 Key strengths 238
12.1.4.4.2 Strategic choices 238
12.1.4.4.3 Weaknesses & competitive threats 238
12.1.5 QIAGEN 239
12.1.5.1 Business overview 239
12.1.5.2 Products offered 240
12.1.5.3 Recent developments 241
12.1.5.3.1 Deals 241
12.1.5.4 MnM view 241
12.1.5.4.1 Key strengths 241
12.1.5.4.2 Strategic choices 241
12.1.5.4.3 Weaknesses & competitive threats 241
12.1.6 MERIT MEDICAL SYSTEMS 242
12.1.6.1 Business overview 242
12.1.6.2 Products offered 243
12.1.6.3 Recent developments 244
12.1.6.3.1 Product launches & approvals 244
12.1.6.3.2 Deals 245
12.1.7 MENARINI SILICON BIOSYSTEMS SPA 246
12.1.7.1 Business overview 246
12.1.7.2 Products offered 246
12.1.7.3 Recent developments 247
12.1.7.3.1 Product launches & approvals 247
12.1.7.3.2 Deals 247
12.1.8 GUARDANT HEALTH, INC. 248
12.1.8.1 Business overview 248
12.1.8.2 Products offered 249
12.1.8.3 Recent developments 250
12.1.8.3.1 Product launches & approvals 250
12.1.8.3.2 Deals 250
12.1.8.3.3 Other developments 251
12.1.9 NEOGENOMICS LABORATORIES, INC. 252
12.1.9.1 Business overview 252
12.1.9.2 Products offered 253
12.1.9.3 Recent developments 253
12.1.9.3.1 Product launches & approvals 253
12.1.9.3.2 Deals 254
12.1.10 STERYLAB S.R.L 255
12.1.10.1 Business overview 255
12.1.10.2 Products offered 255
12.1.11 BIOCEPT, INC. 256
12.1.11.1 Business overview 256
12.1.11.2 Products offered 256
12.1.12 BIO-RAD LABORATORIES, INC. 258
12.1.12.1 Business overview 258
12.1.12.2 Products offered 259
12.1.12.3 Recent developments 260
12.1.12.3.1 Product launches & approvals 260
12.1.13 F. HOFFMANN-LA ROCHE LTD. 261
12.1.13.1 Business overview 261
12.1.13.2 Products offered 262
12.1.14 EXACT SCIENCES CORPORATION 263
12.1.14.1 Business overview 263
12.1.14.2 Products offered 264
12.1.14.3 Recent developments 265
12.1.14.3.1 Deals 265
12.1.15 SYSMEX INOSTICS (A SUBSIDIARY OF SYSMEX CORPORATION) 266
12.1.15.1 Business overview 266
12.1.15.2 Products offered 267
12.1.15.3 Recent developments 268
12.1.15.3.1 Deals 268
12.1.16 THERMO FISHER SCIENTIFIC 269
12.1.16.1 Business overview 269
12.1.16.2 Products offered 270
12.1.16.3 Recent developments 271
12.1.16.3.1 Deals 271
12.1.17 FUJIFILM HOLDINGS CORPORATION 272
12.1.17.1 Business overview 272
12.1.17.2 Products offered 273
12.2 OTHER PLAYERS 274
12.2.1 CARDIFF ONCOLOGY INC. 274
12.2.2 MYRIAD GENETICS, INC. 275
12.2.3 ILLUMINA, INC. 276
12.2.4 FLUXION BIOSCIENCES, INC. 277
12.2.5 INRAD, INC. 278
12.2.6 IZI MEDICAL PRODUCTS 279
12.2.7 REMINGTON MEDICAL INC. 280
12.2.8 CP MEDICAL 281
13 APPENDIX 282
13.1 DISCUSSION GUIDE 282
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 286
13.3 CUSTOMIZATION OPTIONS 288
13.4 RELATED REPORTS 288
13.5 AUTHOR DETAILS 289
LIST OF TABLES
TABLE 1 BREAST BIOPSY DEVICES MARKET: STUDY ASSUMPTIONS 44
TABLE 2 BREAST BIOPSY DEVICES MARKET: RISK ANALYSIS 45
TABLE 3 MEDICARE REIMBURSEMENT FOR BREAST BIOPSY 57
TABLE 4 COST AND UTILITY MODEL INPUTS (2022) 58
TABLE 5 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 62
TABLE 6 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 62
TABLE 7 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 62
TABLE 8 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 63
TABLE 9 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 63
TABLE 10 US FDA: MEDICAL DEVICE CLASSIFICATION 64
TABLE 11 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 65
TABLE 12 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 65
TABLE 13 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA 66
TABLE 14 CHINA: CLASSIFICATION OF MEDICAL DEVICES 67
TABLE 15 BREAST BIOPSY DEVICES MARKET: ROLE IN ECOSYSTEM 72
TABLE 16 IMPORT DATA FOR NEEDLES, CATHETERS, AND CANNULAE (HS CODE 901839),
BY COUNTRY, 2020–2024 (USD THOUSAND) 75
TABLE 17 EXPORT DATA FOR BREAST BIOPSY DEVICES (HS CODE 901839), BY COUNTRY, 2020–2024 (USD THOUSAND) 75
TABLE 18 BREAST BIOPSY DEVICES MARKET: PORTER’S FIVE FORCES ANALYSIS 77
TABLE 19 INDICATIVE SELLING PRICE TREND OF BREAST BIOPSY DEVICES, BY REGION, 2022–2024 (USD) 80
TABLE 20 AVERAGE SELLING PRICE OF BREAST BIOPSY DEVICES,
BY KEY PLAYER, 2024 (USD) 81
TABLE 21 BREAST BIOPSY DEVICES MARKET: LIST OF MAJOR CONFERENCES & EVENTS 83
TABLE 22 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF BREAST BIOPSY DEVICES, BY TOP THREE END USERS 85
TABLE 23 KEY BUYING CRITERIA FOR TOP THREE END USERS OF BREAST BIOPSY DEVICES 85
TABLE 24 US-ADJUSTED RECIPROCAL TARIFF RATES 86
TABLE 25 BREAST BIOPSY DEVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 93
TABLE 26 NEEDLE BREAST BIOPSY DEVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 94
TABLE 27 CORE NEEDLE BIOPSY DEVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 95
TABLE 28 VACUUM-ASSISTED BIOPSY DEVICES MARKET, BY REGION,
2023–2030 (USD MILLION) 96
TABLE 29 FINE NEEDLE ASPIRATION BIOPSY DEVICES MARKET, BY REGION,
2023–2030 (USD MILLION) 97
TABLE 30 OPEN SURGICAL BREAST BIOPSY DEVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 97
TABLE 31 EXCISIONAL BIOPSY DEVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 98
TABLE 32 INCISIONAL BIOPSY DEVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 99
TABLE 33 LIQUID BREAST BIOPSY DEVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 99
TABLE 34 LIQUID BREAST BIOPSY DEVICES MARKET FOR CIRCULATING TUMOR CELLS,
BY REGION, 2023–2030 (USD MILLION) 100
TABLE 35 LIQUID BREAST BIOPSY DEVICES MARKET FOR CIRCULATING TUMOR DNA,
BY REGION, 2023–2030 (USD MILLION) 101
TABLE 36 LIQUID BREAST BIOPSY DEVICES MARKET FOR OTHER BIOMARKERS,
BY REGION, 2023–2030 (USD MILLION) 102
TABLE 37 BREAST BIOPSY DEVICES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 104
TABLE 38 BREAST BIOPSY DEVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 104
TABLE 39 BREAST BIOPSY DEVICES MARKET FOR BIOPSY NEEDLES, BY REGION,
2023–2030 (USD MILLION) 105
TABLE 40 BREAST BIOPSY DEVICES MARKET FOR BIOPSY NEEDLES, BY TYPE,
2023–2030 (USD MILLION) 106
TABLE 41 BREAST BIOPSY DEVICES MARKET FOR CORE NEEDLES, BY REGION,
2023–2030 (USD MILLION) 106
TABLE 42 BREAST BIOPSY DEVICES MARKET FOR FINE ASPIRATION NEEDLES,
BY REGION, 2023–2030 (USD MILLION) 107
TABLE 43 BREAST BIOPSY DEVICES MARKET FOR VACUUM-ASSISTED NEEDLES,
BY REGION, 2023–2030 (USD MILLION) 108
TABLE 44 BREAST BIOPSY DEVICES MARKET FOR BIOPSY EQUIPMENT, BY REGION,
2023–2030 (USD MILLION) 109
TABLE 45 BREAST BIOPSY DEVICES MARKET FOR BIOPSY EQUIPMENT, BY TYPE,
2023–2030 (USD MILLION) 109
TABLE 46 BREAST BIOPSY DEVICES MARKET FOR CORE BIOPSY EQUIPMENT, BY REGION, 2023–2030 (USD MILLION) 110
TABLE 47 BREAST BIOPSY DEVICES MARKET FOR VACUUM-ASSISTED BIOPSY EQUIPMENT, BY REGION, 2023–2030 (USD MILLION) 111
TABLE 48 BREAST BIOPSY DEVICES MARKET FOR GUIDANCE SYSTEMS, BY REGION,
2023–2030 (USD MILLION) 112
TABLE 49 BREAST BIOPSY DEVICES MARKET FOR GUIDANCE SYSTEMS, BY TYPE,
2023–2030 (USD MILLION) 112
TABLE 50 BREAST BIOPSY DEVICES MARKET FOR MAMMOGRAPHY-GUIDED STEREOTACTIC BIOPSY, BY REGION, 2023–2030 (USD MILLION) 113
TABLE 51 BREAST BIOPSY DEVICES MARKET FOR ULTRASOUND-GUIDED BIOPSY, BY REGION, 2023–2030 (USD MILLION) 113
TABLE 52 BREAST BIOPSY DEVICES MARKET FOR MRI-GUIDED BIOPSY, BY REGION,
2023–2030 (USD MILLION) 114
TABLE 53 BREAST BIOPSY DEVICES MARKET FOR BIOPSY TABLES, BY REGION,
2023–2030 (USD MILLION) 115
TABLE 54 BREAST BIOPSY DEVICES MARKET FOR ASSAY KITS, BY REGION,
2023–2030 (USD MILLION) 116
TABLE 55 BREAST BIOPSY DEVICES MARKET FOR LIQUID BIOPSY INSTRUMENTS, BY REGION, 2023–2030 (USD MILLION) 117
TABLE 56 BREAST BIOPSY DEVICES MARKET FOR LOCALIZATION WIRES, BY REGION,
2023–2030 (USD MILLION) 118
TABLE 57 BREAST BIOPSY DEVICES MARKET FOR OTHER PRODUCTS, BY REGION,
2023–2030 (USD MILLION) 118
TABLE 58 BREAST BIOPSY DEVICES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 120
TABLE 59 BREAST BIOPSY DEVICES MARKET FOR EARLY CANCER SCREENING, BY REGION, 2023–2030 (USD MILLION) 121
TABLE 60 BREAST BIOPSY DEVICES MARKET FOR THERAPY SELECTION, BY REGION,
2023–2030 (USD MILLION) 121
TABLE 61 BREAST BIOPSY DEVICES MARKET FOR TREATMENT MONITORING, BY REGION, 2023–2030 (USD MILLION) 122
TABLE 62 BREAST BIOPSY DEVICES MARKET FOR RECURRENCE MONITORING, BY REGION, 2023–2030 (USD MILLION) 123
TABLE 63 BREAST BIOPSY DEVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 125
TABLE 64 BREAST BIOPSY DEVICES MARKET FOR HOSPITALS & CLINICS, BY REGION,
2023–2030 (USD MILLION) 126
TABLE 65 BREAST BIOPSY DEVICES MARKET FOR IMAGING CLINICS & DIAGNOSTIC CENTERS, BY REGION, 2023–2030 (USD MILLION) 127
TABLE 66 BREAST BIOPSY DEVICES MARKET FOR BREAST CARE CENTERS, BY REGION, 2023–2030 (USD MILLION) 128
TABLE 67 BREAST BIOPSY DEVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 130
TABLE 68 TOTAL NUMBER OF BREAST BIOPSY PROCEDURES BY REGION, 2024 131
TABLE 69 VACCUM ASSISTED BIOPSY NEEDLES MARKET, REGION,
2023–2030 (USD MILLION) 131
TABLE 70 NA BREAST BIOPSY DEVICES MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 131
TABLE 71 NORTH AMERICA: MACROINDICATORS 132
TABLE 72 NORTH AMERICA: BREAST BIOPSY DEVICES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 134
TABLE 73 NORTH AMERICA: BREAST BIOPSY DEVICES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 134
TABLE 74 NORTH AMERICA: BREAST BIOPSY DEVICES MARKET, BY PROCEDURE,
2023–2030 (USD MILLION) 135
TABLE 75 NORTH AMERICA: NEEDLE BREAST BIOPSY DEVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 135
TABLE 76 NORTH AMERICA: BREAST BIOPSY DEVICES MARKET FOR BIOPSY EQUIPMENT,
BY TYPE, 2023–2030 (USD MILLION) 136
TABLE 77 NORTH AMERICA: BREAST BIOPSY DEVICES MARKET FOR GUIDANCE SYSTEMS,
BY TYPE, 2023–2030 (USD MILLION) 136
TABLE 78 NORTH AMERICA: BREAST BIOPSY DEVICES MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 137
TABLE 79 NORTH AMERICA: BREAST BIOPSY DEVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 137
TABLE 80 US: BREAST BIOPSY DEVICES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 138
TABLE 81 US: NEEDLE BREAST BIOPSY DEVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 139
TABLE 82 US: BREAST BIOPSY DEVICES MARKET FOR BIOPSY EQUIPMENT, BY TYPE,
2023–2030 (USD MILLION) 139
TABLE 83 US: BREAST BIOPSY DEVICES MARKET FOR GUIDANCE SYSTEMS, BY TYPE,
2023–2030 (USD MILLION) 140
TABLE 84 CANADA: BREAST BIOPSY DEVICES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 141
TABLE 85 CANDA: NEEDLE BREAST BIOPSY DEVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 141
TABLE 86 CANADA: BREAST BIOPSY DEVICES MARKET FOR BIOPSY EQUIPMENT,
BY TYPE, 2023–2030 (USD MILLION) 142
TABLE 87 CANADA: BREAST BIOPSY DEVICES MARKET FOR GUIDANCE SYSTEMS,
BY TYPE, 2023–2030 (USD MILLION) 142
TABLE 88 EUROPE: MACROINDICATORS 143
TABLE 89 EUROPE: BREAST BIOPSY DEVICES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 143
TABLE 90 EUROPE: BREAST BIOPSY DEVICES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 144
TABLE 91 EUROPE: BREAST BIOPSY DEVICES MARKET, BY PROCEDURE,
2023–2030 (USD MILLION) 144
TABLE 92 EUROPE: NEEDLE BREAST BIOPSY DEVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 145
TABLE 93 EUROPE: BREAST BIOPSY DEVICES MARKET FOR BIOPSY EQUIPMENT, BY TYPE, 2023–2030 (USD MILLION) 145
TABLE 94 EUROPE: BREAST BIOPSY DEVICES MARKET FOR GUIDANCE SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 146
TABLE 95 EUROPE: BREAST BIOPSY DEVICES MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 146
TABLE 96 EUROPE: BREAST BIOPSY DEVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 147
TABLE 97 GERMANY: BREAST BIOPSY DEVICES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 148
TABLE 98 GERMANY: NEEDLE BREAST BIOPSY DEVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 148
TABLE 99 GERMANY: BREAST BIOPSY DEVICES MARKET FOR BIOPSY EQUIPMENT, BY TYPE, 2023–2030 (USD MILLION) 149
TABLE 100 GERMANY: BREAST BIOPSY DEVICES MARKET FOR GUIDANCE SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 149
TABLE 101 UK: BREAST BIOPSY DEVICES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 150
TABLE 102 UK: NEEDLE BREAST BIOPSY DEVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 151
TABLE 103 UK: BREAST BIOPSY DEVICES MARKET FOR BIOPSY EQUIPMENT, BY TYPE,
2023–2030 (USD MILLION) 151
TABLE 104 UK: BREAST BIOPSY DEVICES MARKET FOR GUIDANCE SYSTEMS, BY TYPE,
2023–2030 (USD MILLION) 152
TABLE 105 FRANCE: BREAST BIOPSY DEVICES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 153
TABLE 106 FRANCE: NEEDLE BREAST BIOPSY DEVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 153
TABLE 107 FRANCE: BREAST BIOPSY DEVICES MARKET FOR BIOPSY EQUIPMENT, BY TYPE, 2023–2030 (USD MILLION) 154
TABLE 108 FRANCE: BREAST BIOPSY DEVICES MARKET FOR GUIDANCE SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 154
TABLE 109 ITALY: BREAST BIOPSY DEVICES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 155
TABLE 110 ITALY: NEEDLE BREAST BIOPSY DEVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 156
TABLE 111 ITALY BREAST BIOPSY DEVICES MARKET FOR BIOPSY EQUIPMENT, BY TYPE, 2023–2030 (USD MILLION) 156
TABLE 112 ITALY: BREAST BIOPSY DEVICES MARKET FOR GUIDANCE SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 157
TABLE 113 SPAIN: BREAST BIOPSY DEVICES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 158
TABLE 114 SPAIN: NEEDLE BREAST BIOPSY DEVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 158
TABLE 115 SPAIN: BREAST BIOPSY DEVICES MARKET FOR BIOPSY EQUIPMENT, BY TYPE, 2023–2030 (USD MILLION) 159
TABLE 116 SPAIN: BREAST BIOPSY DEVICES MARKET FOR GUIDANCE SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 159
TABLE 117 REST OF EUROPE: BREAST BIOPSY DEVICES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 160
TABLE 118 REST OF EUROPE: NEEDLE BREAST BIOPSY DEVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 160
TABLE 119 REST OF EUROPE: BREAST BIOPSY DEVICES MARKET FOR BIOPSY EQUIPMENT,
BY TYPE, 2023–2030 (USD MILLION) 161
TABLE 120 REST OF EUROPE: BREAST BIOPSY DEVICES MARKET FOR GUIDANCE SYSTEMS,
BY TYPE, 2023–2030 (USD MILLION) 161
TABLE 121 ASIA PACIFIC: MACROINDICATORS 162
TABLE 122 ASIA PACIFIC: BREAST BIOPSY DEVICES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 164
TABLE 123 ASIA PACIFIC: BREAST BIOPSY DEVICES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 164
TABLE 124 ASIA PACIFIC: BREAST BIOPSY DEVICES MARKET, BY PROCEDURE,
2023–2030 (USD MILLION) 165
TABLE 125 ASIA PACIFIC: NEEDLE BREAST BIOPSY DEVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 165
TABLE 126 ASIA PACIFIC: BREAST BIOPSY DEVICES MARKET FOR BIOPSY EQUIPMENT,
BY TYPE, 2023–2030 (USD MILLION) 166
TABLE 127 ASIA PACIFIC: BREAST BIOPSY DEVICES MARKET FOR GUIDANCE SYSTEMS,
BY TYPE, 2023–2030 (USD MILLION) 166
TABLE 128 ASIA PACIFIC: BREAST BIOPSY DEVICES MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 167
TABLE 129 ASIA PACIFIC: BREAST BIOPSY DEVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 167
TABLE 130 CHINA: BREAST BIOPSY DEVICES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 168
TABLE 131 CHINA: NEEDLE BREAST BIOPSY DEVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 169
TABLE 132 CHINA: BREAST BIOPSY DEVICES MARKET FOR BIOPSY EQUIPMENT, BY TYPE, 2023–2030 (USD MILLION) 169
TABLE 133 CHINA: BREAST BIOPSY DEVICES MARKET FOR GUIDANCE SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 170
TABLE 134 JAPAN: BREAST BIOPSY DEVICES MARKET, BY PRODUCT, 2023–2030 171
TABLE 135 JAPAN: NEEDLE BREAST BIOPSY DEVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 171
TABLE 136 JAPAN: BREAST BIOPSY DEVICES MARKET FOR BIOPSY EQUIPMENT, BY TYPE, 2023–2030 (USD MILLION) 172
TABLE 137 JAPAN: BREAST BIOPSY DEVICES MARKET FOR GUIDANCE SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 172
TABLE 138 INDIA: BREAST BIOPSY DEVICES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 173
TABLE 139 INDIA: NEEDLE BREAST BIOPSY DEVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 174
TABLE 140 INDIA: BREAST BIOPSY DEVICES MARKET FOR BIOPSY EQUIPMENT,
BY TYPE, 2023–2030 (USD MILLION) 174
TABLE 141 INDIA: BREAST BIOPSY DEVICES MARKET FOR GUIDANCE SYSTEMS,
BY TYPE, 2023–2030 (USD MILLION) 175
TABLE 142 AUSTRALIA: BREAST BIOPSY DEVICES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 176
TABLE 143 AUSTRALIA: NEEDLE BREAST BIOPSY DEVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 176
TABLE 144 AUSTRALIA: BREAST BIOPSY DEVICES MARKET FOR BIOPSY EQUIPMENT, BY TYPE, 2023–2030 (USD MILLION) 177
TABLE 145 AUSTRALIA: BREAST BIOPSY DEVICES MARKET FOR GUIDANCE SYSTEMS,
BY TYPE, 2023–2030 (USD MILLION) 177
TABLE 146 SOUTH KOREA: BREAST BIOPSY DEVICES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 178
TABLE 147 SOUTH KOREA: NEEDLE BREAST BIOPSY DEVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 178
TABLE 148 SOUTH KOREA: BREAST BIOPSY DEVICES MARKET FOR BIOPSY EQUIPMENT,
BY TYPE, 2023–2030 (USD MILLION) 179
TABLE 149 SOUTH KOREA: BREAST BIOPSY DEVICES MARKET FOR GUIDANCE SYSTEMS,
BY TYPE, 2023–2030 (USD MILLION) 179
TABLE 150 REST OF ASIA PACIFIC: BREAST BIOPSY DEVICES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 180
TABLE 151 REST OF ASIA PACIFIC: NEEDLE BREAST BIOPSY DEVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 180
TABLE 152 REST OF ASIA PACIFIC: BREAST BIOPSY DEVICES MARKET FOR BIOPSY EQUIPMENT, BY TYPE, 2023–2030 (USD MILLION) 181
TABLE 153 REST OF ASIA PACIFIC: BREAST BIOPSY DEVICES MARKET FOR GUIDANCE SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 181
TABLE 154 LATIN AMERICA: MACROINDICATORS 182
TABLE 155 LATIN AMERICA: BREAST BIOPSY DEVICES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 182
TABLE 156 LATIN AMERICA: BREAST BIOPSY DEVICES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 183
TABLE 157 LATIN AMERICA: BREAST BIOPSY DEVICES MARKET, BY PROCEDURE,
2023–2030 (USD MILLION) 183
TABLE 158 LATIN AMERICA: NEEDLE BREAST BIOPSY DEVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 184
TABLE 159 LATIN AMERICA: BREAST BIOPSY DEVICES MARKET FOR BIOPSY EQUIPMENT,
BY TYPE, 2023–2030 (USD MILLION) 184
TABLE 160 LATIN AMERICA: BREAST BIOPSY DEVICES MARKET FOR GUIDANCE SYSTEMS,
BY TYPE, 2023–2030 (USD MILLION) 185
TABLE 161 LATIN AMERICA: BREAST BIOPSY DEVICES MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 185
TABLE 162 LATIN AMERICA: BREAST BIOPSY DEVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 186
TABLE 163 BRAZIL: BREAST BIOPSY DEVICES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 187
TABLE 164 BRAZIL: NEEDLE BREAST BIOPSY DEVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 187
TABLE 165 BRAZIL: BREAST BIOPSY DEVICES MARKET FOR BIOPSY EQUIPMENT, BY TYPE, 2023–2030 (USD MILLION) 188
TABLE 166 BRAZIL: BREAST BIOPSY DEVICES MARKET FOR GUIDANCE SYSTEMS,
BY TYPE, 2023–2030 (USD MILLION) 188
TABLE 167 MEXICO: BREAST BIOPSY DEVICES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 189
TABLE 168 MEXICO: NEEDLE BREAST BIOPSY DEVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 189
TABLE 169 MEXICO: BREAST BIOPSY DEVICES MARKET FOR BIOPSY EQUIPMENT,
BY TYPE, 2023–2030 (USD MILLION) 190
TABLE 170 MEXICO: BREAST BIOPSY DEVICES MARKET FOR GUIDANCE SYSTEMS,
BY TYPE, 2023–2030 (USD MILLION) 190
TABLE 171 REST OF LATIN AMERICA: BREAST BIOPSY DEVICES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 191
TABLE 172 REST OF LATIN AMERICA: NEEDLE BREAST BIOPSY DEVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 191
TABLE 173 REST OF LATIN AMERICA: BREAST BIOPSY DEVICES MARKET FOR BIOPSY EQUIPMENT, BY TYPE, 2023–2030 (USD MILLION) 192
TABLE 174 REST OF LATIN AMERICA: BREAST BIOPSY DEVICES MARKET FOR GUIDANCE SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 192
TABLE 175 MIDDLE EAST & AFRICA: KEY MACROINDICATORS 193
TABLE 176 MIDDLE EAST & AFRICA: BREAST BIOPSY DEVICES MARKET, BY REGION,
2023–2030 (USD MILLION) 193
TABLE 177 MIDDLE EAST & AFRICA: BREAST BIOPSY DEVICES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 194
TABLE 178 MIDDLE EAST & AFRICA: BREAST BIOPSY DEVICES MARKET, BY PROCEDURE, 2023–2030 (USD MILLION) 194
TABLE 179 MIDDLE EAST & AFRICA: NEEDLE BREAST BIOPSY DEVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 195
TABLE 180 MIDDLE EAST & AFRICA: BREAST BIOPSY DEVICES MARKET FOR BIOPSY EQUIPMENT, BY TYPE, 2023–2030 (USD MILLION) 195
TABLE 181 MIDDLE EAST & AFRICA: BREAST BIOPSY DEVICES MARKET FOR GUIDANCE SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 196
TABLE 182 MIDDLE EAST & AFRICA: BREAST BIOPSY DEVICES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 196
TABLE 183 MIDDLE EAST & AFRICA: BREAST BIOPSY DEVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 197
TABLE 184 GCC COUNTRIES: BREAST BIOPSY DEVICES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 197
TABLE 185 GCC COUNTRIES: NEEDLE BREAST BIOPSY DEVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 198
TABLE 186 GCC COUNTRIES: BREAST BIOPSY DEVICES MARKET FOR BIOPSY EQUIPMENT,
BY TYPE, 2023–2030 (USD MILLION) 198
TABLE 187 GCC COUNTRIES: BREAST BIOPSY DEVICES MARKET FOR GUIDANCE SYSTEMS,
BY TYPE, 2023–2030 (USD MILLION) 199
TABLE 188 REST OF MIDDLE EAST & AFRICA: BREAST BIOPSY DEVICES MARKET,
BY PRODUCT, 2023–2030 (USD MILLION) 200
TABLE 189 REST OF MIDDLE EAST & AFRICA: NEEDLE BREAST BIOPSY DEVICES MARKET,
BY TYPE, 2023–2030 (USD MILLION) 200
TABLE 190 REST OF MIDDLE EAST & AFRICA: BREAST BIOPSY DEVICES MARKET FOR BIOPSY EQUIPMENT, BY TYPE, 2023–2030 (USD MILLION) 201
TABLE 191 REST OF MIDDLE EAST & AFRICA: BREAST BIOPSY DEVICES MARKET FOR GUIDANCE SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 201
TABLE 192 OVERVIEW OF STRATEGIES DEPLOYED BY KEY BREAST BIOPSY DEVICE MANUFACTURING COMPANIES 203
TABLE 193 BREAST BIOPSY DEVICES MARKET: DEGREE OF COMPETITION 206
TABLE 194 BREAST BIOPSY DEVICES MARKET: REGION FOOTPRINT 211
TABLE 195 BREAST BIOPSY DEVICES MARKET: PRODUCT FOOTPRINT 212
TABLE 196 BREAST BIOPSY DEVICES MARKET: PROCEDURE FOOTPRINT 213
TABLE 197 BREAST BIOPSY DEVICES MARKET: APPLICATION FOOTPRINT 214
TABLE 198 BREAST BIOPSY DEVICES MARKET: END USER FOOTPRINT 215
TABLE 199 BREAST BIOPSY DEVICES MARKET: DETAILED LIST OF KEY STARTUPS/SMES 218
TABLE 200 BREAST BIOPSY DEVICES MARKET: COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS, BY REGION 218
TABLE 201 BREAST BIOPSY DEVICES MARKET: COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS, BY PRODUCT 219
TABLE 202 BREAST BIOPSY DEVICES MARKET: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2021–MAY 2025 222
TABLE 203 BREAST BIOPSY DEVICES MARKET: DEALS, JANUARY 2021–MAY 2025 223
TABLE 204 HOLOGIC, INC. BUSINESS OVERVIEW 224
TABLE 205 HOLOGIC, INC.: PRODUCTS OFFERED 225
TABLE 206 HOLOGIC, INC.: DEALS, JANUARY 2021–MAY 2025 226
TABLE 207 DANAHER CORPORATION: COMPANY OVERVIEW 228
TABLE 208 DANAHER CORPORATION: PRODUCTS OFFERED 229
TABLE 209 DANAHER CORPORATION: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2021–MAY 2025 230
TABLE 210 DANAHER CORPORATION: DEALS, JANUARY 2021–MAY 2025 231
TABLE 211 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW 233
TABLE 212 BECTON, DICKINSON AND COMPANY: PRODUCTS OFFERED 234
TABLE 213 ARGON MEDICAL: COMPANY OVERVIEW 236
TABLE 214 ARGON MEDICAL: PRODUCTS OFFERED 236
TABLE 215 ARGON MEDICAL: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–MAY 2025 237
TABLE 216 ARGON MEDICAL: DEALS, JANUARY 2021–MAY 2025 237
TABLE 217 QIAGEN: COMPANY OVERVIEW 239
TABLE 218 QIAGEN: PRODUCTS OFFERED 240
TABLE 219 QIAGEN: DEALS, JANUARY 2021–MAY 2025 241
TABLE 220 MERIT MEDICAL SYSTEMS: COMPANY OVERVIEW 242
TABLE 221 MERIT MEDICAL SYSTEMS: PRODUCTS OFFERED 243
TABLE 222 MERIT MEDICAL SYSTEMS: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2021–MAY 2025 244
TABLE 223 MERIT MEDICAL SYSTEMS: DEALS, JANUARY 2021–MAY 2025 245
TABLE 224 MENARINI SILICON BIOSYSTEMS SPA: COMPANY OVERVIEW 246
TABLE 225 MENARINI SILICON BIOSYSTEMS SPA: PRODUCTS OFFERED 246
TABLE 226 MENARINI SILICON BIOSYSTEMS SPA: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–MAY 2025 247
TABLE 227 MENARINI SILICON BIOSYSTEMS SPA: DEALS, JANUARY 2021–MAY 2025 247
TABLE 228 GUARDANT HEALTH, INC.: COMPANY OVERVIEW 248
TABLE 229 GUARDANT HEALTH, INC.: PRODUCTS OFFERED 249
TABLE 230 GUARDANT HEALTH, INC.: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2021–MAY 2025 250
TABLE 231 GUARDANT HEALTH, INC.: DEALS, JANUARY 2021–MAY 2025 250
TABLE 232 GUARDANT HEALTH, INC.: OTHER DEVELOPMENTS, JANUARY 2021–MAY 2025 251
TABLE 233 NEOGENOMICS LABORATORIES, INC.: COMPANY OVERVIEW 252
TABLE 234 NEOGENOMICS LABORATORIES, INC.: PRODUCTS OFFERED 253
TABLE 235 NEOGENOMICS LABORATORIES, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–MAY 2025 253
TABLE 236 NEOGENOMICS LABORATORIES, INC.: DEALS, JANUARY 2021–MAY 2025 254
TABLE 237 STERYLAB S.R.L: COMPANY OVERVIEW 255
TABLE 238 STERYLAB S.R.L: PRODUCTS OFFERED 255
TABLE 239 BIOCEPT, INC.: COMPANY OVERVIEW 256
TABLE 240 BIOCEPT, INC.: PRODUCTS OFFERED 256
TABLE 241 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW 258
TABLE 242 BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED 259
TABLE 243 BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2021–MAY 2025 260
TABLE 244 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 261
TABLE 245 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED 262
TABLE 246 EXACT SCIENCES CORPORATION: COMPANY OVERVIEW 263
TABLE 247 EXACT SCIENCES CORPORATION: PRODUCTS OFFERED 264
TABLE 248 EXACT SCIENCES CORPORATION: DEALS, JANUARY 2021–MAY 2025 265
TABLE 249 SYSMEX INOSTICS: COMPANY OVERVIEW 266
TABLE 250 SYSMEX INOSTICS: PRODUCTS OFFERED 267
TABLE 251 SYSMEX INOSTICS: DEALS, JANUARY 2021–MAY 2025 268
TABLE 252 THERMO FISHER SCIENTIFIC: COMPANY OVERVIEW 269
TABLE 253 THERMO FISHER SCIENTIFIC: PRODUCTS OFFERED 270
TABLE 254 THERMO FISHER SCIENTIFIC: DEALS, JANUARY 2021–MARCH 2024 271
TABLE 255 FUJIFILM HOLDINGS CORPORATION: COMPANY OVERVIEW 272
TABLE 256 FUJIFILM HOLDINGS CORPORATION: PRODUCTS OFFERED 273
TABLE 257 CARDIFF ONCOLOGY INC.: COMPANY OVERVIEW 274
TABLE 258 MYRIAD GENETICS, INC.: COMPANY OVERVIEW 275
TABLE 259 ILLUMINA, INC.: COMPANY OVERVIEW 276
TABLE 260 FLUXION BIOSCIENCES, INC.: COMPANY OVERVIEW 277
TABLE 261 INRAD, INC.: COMPANY OVERVIEW 278
TABLE 262 IZI MEDICAL PRODUCTS: COMPANY OVERVIEW 279
TABLE 263 REMINGTON MEDICAL INC.: COMPANY OVERVIEW 280
TABLE 264 CP MEDICAL: COMPANY OVERVIEW 281
LIST OF FIGURES
FIGURE 1 BREAST BIOPSY DEVICES MARKET SEGMENTATION & REGIONAL SCOPE 27
FIGURE 2 BREAST BIOPSY DEVICES MARKET: RESEARCH DATA 31
FIGURE 3 BREAST BIOPSY DEVICES MARKET: RESEARCH DESIGN 32
FIGURE 4 BREAST BIOPSY DEVICES MARKET: KEY DATA FROM SECONDARY SOURCES 34
FIGURE 5 BREAST BIOPSY DEVICES MARKET: PRIMARY SOURCES 35
FIGURE 6 BREAST BIOPSY DEVICES MARKET: KEY INDUSTRY INSIGHTS 36
FIGURE 7 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,
DESIGNATION, AND REGION 36
FIGURE 8 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS 37
FIGURE 9 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 38
FIGURE 10 BREAST BIOPSY DEVICES MARKET SIZE ESTIMATION: BOTTOM-UP
APPROACH (REVENUE SHARE ANALYSIS) 39
FIGURE 11 BREAST BIOPSY DEVICES MARKET SIZE ESTIMATION: COMPANY
REVENUE ESTIMATION 40
FIGURE 12 BREAST BIOPSY DEVICES MARKET: TOP-DOWN APPROACH 41
FIGURE 13 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 42
FIGURE 14 BREAST BIOPSY DEVICES MARKET: DATA TRIANGULATION 43
FIGURE 15 BREAST BIOPSY DEVICES MARKET, BY PRODUCT, 2025 VS. 2030 (USD MILLION) 46
FIGURE 16 BREAST BIOPSY DEVICES MARKET, BY PROCEDURE,
2025 VS. 2030 (USD MILLION) 47
FIGURE 17 BREAST BIOPSY PROCEDURE GROWTH [ BIOPSY PROCEDURES IN ‘000S VS FEMALES AGED 40 – 69 YEARS IN MILLIONS (2023) ] 47
FIGURE 18 BREAST BIOPSY DEVICES MARKET, BY APPLICATION,
2025 VS. 2030 (USD MILLION) 48
FIGURE 19 BREAST BIOPSY DEVICES MARKET, BY END USER, 2025 VS. 2030 (USD MILLION) 48
FIGURE 20 BREAST BIOPSY DEVICES MARKET: REGIONAL SNAPSHOT 49
FIGURE 21 GROWING INCIDENCE OF BREAST CANCER TO DRIVE MARKET 50
FIGURE 22 NORTH AMERICA TO ACCOUNT FOR LARGEST SHARE OF MARKET DURING FORECAST PERIOD 51
FIGURE 23 EARLY CANCER SCREENING SEGMENT ACCOUNTED FOR LARGEST
MARKET SHARE IN 2024 52
FIGURE 24 CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 53
FIGURE 25 BREAST BIOPSY DEVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,
AND CHALLENGES 54
FIGURE 26 VALUE CHAIN ANALYSIS—MAXIMUM VALUE ADDED DURING
MANUFACTURING PHASE 69
FIGURE 27 BREAST BIOPSY DEVICES MARKET: SUPPLY CHAIN ANALYSIS 70
FIGURE 28 BREAST BIOPSY DEVICES MARKET: ECOSYSTEM ANALYSIS 71
FIGURE 29 PATENT DETAILS FOR BREAST BIOPSY DEVICES (JANUARY 2013–MAY 2025) 76
FIGURE 30 BREAST BIOPSY DEVICES MARKET: PORTER’S FIVE FORCES ANALYSIS 77
FIGURE 31 AVERAGE SELLING PRICE TREND OF BREAST BIOPSY DEVICES,
BY REGION, 2022–2024 (USD) 79
FIGURE 32 AVERAGE SELLING PRICE OF BREAST BIOPSY DEVICES,
BY KEY PLAYER, 2024 (USD) 81
FIGURE 33 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF BREAST BIOPSY DEVICES, BY TOP THREE END USERS 84
FIGURE 34 KEY BUYING CRITERIA FOR TOP THREE END USERS OF BREAST BIOPSY DEVICES 85
FIGURE 35 BREAST BIOPSY DEVICES: INVESTMENT & FUNDING SCENARIO 90
FIGURE 36 NUMBER OF INVESTOR DEALS, BY KEY PLAYER, 2019–2023 90
FIGURE 37 VALUE OF INVESTOR DEALS, BY KEY PLAYER, 2018–2022 (USD MILLION) 91
FIGURE 38 NORTH AMERICA: BREAST BIOPSY DEVICES MARKET SNAPSHOT 133
FIGURE 39 ASIA PACIFIC: BREAST BIOPSY DEVICES MARKET SNAPSHOT 163
FIGURE 40 REVENUE ANALYSIS OF TOP 5 PLAYERS IN BREAST BIOPSY
DEVICES MARKET, 2020–2024 205
FIGURE 41 MARKET SHARE ANALYSIS OF KEY PLAYERS IN BREAST BIOPSY
DEVICES MARKET (2024) 205
FIGURE 42 BREAST BIOPSY DEVICES MARKET: COMPANY EVALUATION
MATRIX (KEY PLAYERS), 2024 209
FIGURE 43 BREAST BIOPSY DEVICES MARKET: COMPANY FOOTPRINT 210
FIGURE 44 BREAST BIOPSY DEVICES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 217
FIGURE 45 EV/EBITDA OF KEY VENDORS 220
FIGURE 46 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK
BETA OF KEY VENDORS 220
FIGURE 47 BREAST BIOPSY DEVICES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 221
FIGURE 48 HOLOGIC, INC.: COMPANY SNAPSHOT (2024) 225
FIGURE 49 DANAHER CORPORATION: COMPANY SNAPSHOT (2024) 229
FIGURE 50 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2024) 234
FIGURE 51 QIAGEN: COMPANY SNAPSHOT (2024) 240
FIGURE 52 MERIT MEDICAL SYSTEMS: COMPANY SNAPSHOT (2024) 243
FIGURE 53 GUARDANT HEALTH, INC.: COMPANY SNAPSHOT (2024) 249
FIGURE 54 NEOGENOMICS LABORATORIES, INC.: COMPANY SNAPSHOT (2023) 252
FIGURE 55 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2024) 259
FIGURE 56 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2024) 262
FIGURE 57 EXACT SCIENCES CORPORATION: COMPANY SNAPSHOT (2024) 264
FIGURE 58 SYSMEX INOSTICS: COMPANY SNAPSHOT (2024) 267
FIGURE 59 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2024) 270
FIGURE 60 FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT (2024) 273
MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。
※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD8,150 | お問合せください | お問合せください | お問合せください |
ライセンスタイプ4
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
| シングルユーザ | コーポレート |
| USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
- 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
- ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11